Skip to content

Insmed INSM Return on equity

Return on equity at other companies

United Therapeutics logo
United TherapeuticsUTHR
20.3%+0.3pp
Incyte logo
IncyteINCY
30.8%+30.4pp
Amgen logo
AmgenAMGN
101.3%-4.4pp
ALN
Alnylam PharmaceuticalsALNY
66.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
22.5%+10.1pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%-3.0pp

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$21.34B+155%
Enterprise value$21.34B+142%
P/S26×+4.1×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp

Returns & leverage

See full
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Calculated from Insmed’s reported figures.

Based on trailing twelve months.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's return on equity?
Insmed (INSM) reported return on equity of -294.5% in Q1 2026.
What does return on equity mean?
How much profit the company earns on the money shareholders have invested.
How do you interpret return on equity?
Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
How does return on equity compare across companies?
Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.